Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1387-1393

  Yang, Bing Bing ^a   Kido, Anna ^a   Shibata, Atsuko ^a  

^a AMGEN INC   (United States)

Author keywords

Absolute neutrophil count; ANC; G CSF; Granulocyte colony stimulating factor; Neutropenia; Pegfilgrastim; Serum concentrations

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRANULOPOIESIS; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FILGRASTIM; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; NEOPLASMS; NEUTROPHILS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 34948815669     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1387     Document Type: Article

References (18)

1. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-808.
2. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29.
3. Amgen Inc. Neupogen (filgrastim) prescribing information. Thousand Oaks, CA; 2004.
4. Kuwabara T, Kobayashi S, Sugiyama Y, et al. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 1996;28:625-58.
5. Roskos LK, Cheung EN, Vincent M, et al. Pharmacology of filgrastim (r metHuG-CSF). In: Morstyn G, Dexter TM, Foote M, eds. Filgrastim (r-metHuG-CSF) in clinical practice, 2nd ed. New York: Marcel Dekker, Inc., 1998:51-72.
6. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHuG-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001;7:2085-90.
7. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Current Pharmaceut Design 2004;10:1235-44.
8. Yang BB, Lum PK, Hayashi MM, Roskos LK. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 2004;93:1367-73.
9. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
10. Amgen Inc. Neulasta (pegfilgrastim) prescribing information. Thousand Oaks, CA; 2007.
11. George S, Younnes F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-6.
12. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1503-8.
13. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-19.
14. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9.
15. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage HWV breast cancer. J Clin Oncol 2002;20:727-31.
16. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
17. Roskos LK, Lum P, Lockbaum P, et al. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006;46:747-57.
18. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;24:1724-34.